A Phase II Study of Valemetostat Tosylate in People with Persistent Peripheral T-Cell Lymphoma or Adult T-Cell Leukemia/Lymphoma

Share
Print

Full Title

Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma

Purpose

The purpose of this study is to assess the safety and effectiveness of the investigational drug valemetostat tosylate in people with peripheral T-cell lymphoma (PTCL) or adult T-cell leukemia/lymphoma (ATL) whose cancer has continued to grow or came back despite treatment. Valemetostat tosylate blocks proteins called EZH1 and EZH2. These proteins can help cancer cells grow and survive. By blocking these proteins, valemetostat tosylate may slow or stop the growth of PTCL or ATL. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Patients must have PTCL or ATL that has continued to grow or came back despite treatment.
  • Patients should recover from any serious side effects of prior therapies before taking valemetostat tosylate.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Steven Horwitz at 646-608-3725.

Protocol

21-355

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators